A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs SEL 24 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Selvita
- 08 Oct 2017 Status changed from recruiting to suspended.
- 17 Mar 2017 According to a Selvita company media release, first patient has been dosed in this trial.
- 06 Jan 2017 Status changed from not yet recruiting to recruiting.